Arlington Capital Partners’ portfolio company AVS Bio has acquired ImmunoPrecise Antibodies (Europe) B.V. to enhance its capabilities in the bioprocessing and biologics sectors.

Target Company Overview

ImmunoPrecise Antibodies (Europe) B.V. ("IPA Europe") is a recently carved-out entity from ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a prominent player in the biotherapeutics sector. The company is dedicated to providing critical services such as antibody discovery, engineering, and characterization, along with recombinant protein production. IPA Europe operates state-of-the-art facilities in Utrecht and Oss, Netherlands, and boasts advanced platforms including hybridoma and B-cell screening technologies, which allow for comprehensive support in the development of next-generation biologics.

IPA Europe has established a reputation for technical excellence and a commitment to scientific rigor, positioning itself as a valuable partner for biotechnology and pharmaceutical companies engaged in developing innovative therapeutics, diagnostics, and vaccines. The acquisition by AVS Bio represents a strategic move to enhance their service portfolio and expand their European market presence.

Industry Overview in the Netherlands

The Netherlands has emerged as a key player in the global biotechnology sector, driven by a robust infrastructure for research and development. The country hosts numerous biopharmaceutical companies, providing an ecosystem